Clinical trials: Tace
Unresectable Liver Cancer
Study on the Efficacy and Safety of Transarterial Chemoembolization Combined With Targeted Immunotherapy in Patients With Unresectable Hepatocellular Carcinoma
This study is a single-center, single-arm, prospective study. It enrolls patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT06715072
- Volunteers
- 70 people
- Sponsor
- Yao Xie
Hepatocellular Carcinoma, Pulmonary Metastasis
Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study
This study mainly evaluate the clinical effect of Apatinib in the treatment of patients with pulmonary metastasis of hepatocellular carcinoma.Half of participants will receive Apatinib and transcatheter arterial chemoembolization…
- Trial name
- NCT02702323
- Testing
- Apatinib, TACE
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma
TACE Combined With Penpulimab and Anlotinib for Advanced HCC
The purpose of this multicenter, dual-cohort, prospective real-world study is to explore the efficacy and safety of penpulimab and anlotinib combined with or without TACE, as well as the optimum interval of the combination of…
- Trial name
- NCT05344924
- Testing
- TACE+penpulimab+anlotinib vs. penpulimab+anlotinib
- Where
- China
- Volunteers
- 109 people
- Sponsor
- Zhongda Hospital
Advanced Hepatocellular Carcinoma
Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT
This is a multicentri prospective cohort study to investigate the safety and efficacy of external beam radiation (RT) combined with transarterial chemoembolization (TACE) and lenvatinib vs TACE and lenvatinib in the treatment of…
- Trial name
- NCT05592197
- Testing
- Lenvatinib, TACE, External beam radiation (RT)
- Where
- China
- Sponsor
- Sun Yat-sen University
Unresectable Hepatocellular Carcinoma
Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma
This study is the single-center, open-label phase I clinical trial to evaluate tolerability, safety and efficacy of Donafenib and JS001 in combination with TCAE in patients with Unresectable Hepatocellular Carcinoma.
- Trial name
- NCT04605185
- Testing
- Donafenib Tosilate Tablets, Toripalimab Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Hepatocellular Carcinoma
SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma
This study is open to patients with primary HCC who cannot be treated by potentially curative treatment modalities, such as surgical resection, liver transplantation or percutaneous ablation.
- Trial name
- SIRTACE (NCT00867750)
- Testing
- Radioembolisation (SIR-Spheres® microspheres), Transarterial Chemoembolisation
- Where
- 2 sites in Germany, Spain
- Volunteers
- 28 people
- Sponsor
- Sirtex Medical
Hepatocellular Carcinoma
TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC
The purpose of this study is to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with programmed cell death protein-1 (PD-1) antibody compared with TACE Alone in patients with unresectable…
- Trial name
- NCT03782831
- Testing
- TACE, PD-1 antibody
- Where
- 3 sites in China
- Sponsor
- Sun Yat-sen University
Hepatocellular Cancer (HCC)
Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients
This is a multicenter, retrospective cohort study that aims to evaluate the efficacy and safety of a triple-drug cocktail (TCC), consisting of Thalidomide, Carmofur, and Compound Mylabris Capsules (CMC), in combination with…
- Trial name
- NCT07321613
- Testing
- Thalidomide (50mg), carmofur, compound mylabris capsule
- Where
- China
- Volunteers
- 545 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
This study is conducted to evaluate the efficacy and safety of lenvatinib plus iodine-125 seed brachytherapy (Len-I) compared with lenvatinib (Len) alone for patients with hepatocellular carcinoma (HCC) refractory to…
- Trial name
- NCT05608213
- Testing
- Lenvatinib Plus I-125 Seed Brachytherapy, Lenvatinib
- Where
- China
- Volunteers
- 187 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;
This is a multicenter, randomized, parallel controlled study to determine the efficacy and safety of transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma beyond University of California, San…
- Trial name
- NCT04738188
- Testing
- DEB-TACE, cTACE, Drug-eluting Beads
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)
Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)
A Single center, Open, Randomized Controlled Trial Evaluating the Safety and Efficacy of GSMs-TACE Combined with Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) with Type III Portal Vein Tumor Thrombus…
- Trial name
- NCT04619342
- Testing
- GSMs-TACE, Surgical Resection
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
HCC - Hepatocellular Carcinoma
Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma
ABSTRACT Objective: To detect presence of a residual tumor in patients of hepatocellular carcinoma (HCC) treated with Lipiodol based conventional trans arterial chemoembolization (cTACE) using density measurements on follow-up…
- Trial name
- NCT06602986
- Testing
- TACE
- Where
- Pakistan
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pak Emirates Military Hospital
Hepatocellular Carcinoma
Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not Eligible for Transarterial Chemoembolization or Ablation Prior to Liver Transplant (RADBRI)
Liver transplantation (LT) represents the best treatment for patients with selected, early stage hepatocellular carcinoma (HCC).
- Trial name
- RADBRI (NCT03172559)
- Testing
- Stereotactic body radiotherapy
- Sponsor
- University Health Network, Toronto
Carcinoma, Hepatocellular, Neoplasms, Glandular and Epithelial
Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
This study is a prospective, single-arm, single-center trial evaluating the efficacy of TACE combined with multimodal ablation, Tislelizumab, and lenvatinib in the treatment of unresectable primary liver cancer.
- Conditions
- Carcinoma, Hepatocellular, Neoplasms, Glandular and Epithelial, Adenocarcinoma, Digestive System Neoplasms
- Trial name
- NCT06794073
- Testing
- Multimodal Thermal Therapy
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)
Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. Although resection was recommend for early stage (BCLC A stage) patients according to the BCLC (Barcelona clinical liver cancer) system, increasing…
- Trial name
- NCT04777942
- Testing
- neo-TACE-HAIC+Surgery, Surgery alone
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).
Selective Internal Radiation Therapy is superior to Transarterial Chemoembolisation for the treatment of intermediate stage hepatocellular carcinoma.
- Trial name
- NCT01798160
- Testing
- DEB TACE, SIRT
- Volunteers
- 24 people
- Sponsor
- Johannes Gutenberg University Mainz
Hepatocellular Carcinoma
Sorafenib With TACE to Treat Hepatocellular Carcinoma
The purpose of this study is to determine the feasibility to combine sorafenib with transarterial chemoembolisation in patients suffering from hepatocellular carcinoma.The hypothesis is that sorafenib may prevent the development…
- Trial name
- S-TACE (NCT00478374)
- Testing
- Sorafenib, Transarterial chemoembolisation with doxorubicin
- Where
- Switzerland
- Volunteers
- 21 people
- Sponsor
- University of Bern
Hepatocellular Carcinoma
Role of DEB-TACE Versus c-TACE in Treatment of HCC
Hepatocellular carcinoma (HCC) is listed as the sixth most common cancer worldwide and the third most frequent cause of cancer-related mortality. The majority of HCC cases occurs stem from chronic liver disease and cirrhosis.
- Trial name
- NCT05093920
- Testing
- Doxorubicin-Eluting Beads
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Sohag University
Carcinoma, Hepatocellular
Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC)
Most HCC patients are diagnosed at advanced stages in Korea, transcatheter arterial chemoembolization is considered a key modality for palliative treatment in these HCC patients.
- Trial name
- NCT00919009
- Testing
- TACE (Transcatheter Arterial Chemoembolization )
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- National Cancer Center, Korea
Advanced Hepatocellular Carcinoma
Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients
This study is a single-center, open, single-arm, phase II clinical trial. Eligible HCC patients, after signing informed consent, will receive TACE treatment.
- Trial name
- CISLD-12 (NCT05213221)
- Testing
- Envafolimab, TACE, Lenvatinib
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Zhejiang University